- Drug Coverage
- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Safety & Recalls
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
SHINE Study: Illuminating the Promise of Nusinersen in SMA Treatment
This study explores the background and rationale behind utilizing nusinersen for the treatment of Spinal Muscular Atrophy (SMA), shedding light on the critical need for the SHINE study. Delving into the characteristics of the patient population involved, the research aims to deepen our understanding of the therapeutic potential of nusinersen in addressing SMA, a debilitating genetic disorder.
EP: 1.SHINE Study: Illuminating the Promise of Nusinersen in SMA Treatment
EP: 2.Examining Patient Characteristics from SHINE Study
EP: 3.Highlighting Key Data from the CHERISH and SHINE Studies
EP: 4.Examining Key Findings from NURTURE Study
EP: 5.Relevance of NUTURE Study Findings for Patients, Payers, Providers
EP: 6.Navigating Undefined Parameters for SMA Treatment Coverage
In the "Between the Lines" program, Jim Kenney and Dr. Thomas Crawford discuss the transformative developments in treating spinal muscular atrophy (SMA) through long-term treatment with nusinersen, highlighted by the SHINE and NURTURE studies. Dr. Crawford reflects on the significant progress made over 25 years, turning SMA from a seemingly incurable disease with high mortality rates into a success story in molecular medicine.
Nusinersen, an antisense oligonucleotide (ASO), is a DNA-like molecule introduced intrathecally to modify the splicing of a backup gene in the spinal column, leading to the production of a functional protein. This breakthrough treatment has shifted SMA from a state of minimal protein expression to normal levels, setting a precedent for addressing various genetic diseases.
The conversation delves into the rationale behind the CHERISH and SHINE studies, exploring the challenges of using a novel therapy like nusinersen. Dr. Crawford emphasizes the importance of determining the right dose, frequency, patient selection, and outcome measures. The SHINE study, a compilation of various studies, was designed to harmonize and understand the long-term effects of treating SMA. Unexpectedly successful, the study had to end early due to its remarkable outcomes, leading to its publication in the New England Journal of Medicine.
The SHINE Study, transitioning patients to a single dose of nusinersen, aimed to assess safety and functional outcomes over time. Dr. Crawford explains the study's unique approach, including the blending of patients from previous studies, providing valuable insights into the impact of nusinersen on SMA patients over the long haul. The program showcases the journey from despair to hope in treating SMA and the potential implications for addressing other genetic diseases in the future.
Video synopsis is AI-generated and reviewed by Managed Health Care Executive editorial staff.
Can Lecanemab Succeed Where Aduhelm Failed?
September 28th 2022The announcement of positive phase 3 results for the investigational Alzheimer’s disease drug comes against a backdrop of Aduhelm flaming out. Both drugs are predicated on the theory that Alzheimer’s is caused by beta-amyloid deposits.
Read More
